In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT4 receptor

European Journal of Pharmacology

Volumn 609, Issue 1-3, 2009, Pages 5-12

  Mikami, Tadayoshi ^a   Komada, Tohru ^a   Sugimoto, Hiromi ^a   Suzuki, Keiko ^a   Ohmi, Takashi ^a   Kimura, Naoji ^a   Naganeo, Rie ^a   Nakata, Eriko ^a   Nakatani, Keigo ^a   Toga, Tetsuo ^a   Eda, Hiroyuki ^a   Sakakibara, Minoru ^a  

^a Global Research and Development   (Japan)

Author keywords

5 HT4 receptor; Agonist; Constipation; Gastro esophageal reflux disease; Gastrointestinal motility; Irritable bowel syndrome

Indexed keywords

CISAPRIDE; DOPAMINE 2 RECEPTOR; PF 01354082; POTASSIUM CHANNEL HERG; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3A RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; SEROTONIN 4D RECEPTOR; SEROTONIN 4H RECEPTOR; SEROTONIN 7 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GASTROINTESTINAL DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ION CURRENT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH MOTILITY;

ADMINISTRATION, ORAL; ANIMALS; BENZIMIDAZOLES; CARBACHOL; CELL LINE; CHO CELLS; CHOLINERGIC AGONISTS; CRICETINAE; CRICETULUS; CYCLIC AMP; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGUS; GASTROINTESTINAL MOTILITY; HUMANS; INDOLES; KIDNEY; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PIPERIDINES; RATS; RATS, INBRED STRAINS; RECEPTORS, SEROTONIN, 5-HT4; SENSITIVITY AND SPECIFICITY; SEROTONIN AGONISTS; TIME FACTORS;

EID: 64549160588     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.03.006     Document Type: Article

References (58)

1. Baxter G.S., Craig D.A., and Clarke D.E. 5-Hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae. Naunyn Schmiedeberg's Arch. Pharmacol. 343 (1991) 439-446
2. 2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol. 143 (2004) 549-560
3. Bermudez J., Dunbar A., Sanger G.J., and Turner D.H. Stimulation of canine gastric motility by BRL 24924, a new gastric prokinetic agent. J. Gastrointest. Motil. 2 (1990) 281-286
4. Bertrand P.P., Kunze W.A., Furness J.B., and Bornstein J.C. The terminals of myenteric intrinsic primary afferent neurons of the guinea-pig ileum are excited by 5-hydroxytryptamine acting at 5-hydroxytryptamine-3 receptors. Neuroscience 101 (2000) 459-469
5. 4 receptor function. J. Pharm. Pharmacol. 47 (1995) 219-222
6. 2B receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br. J. Pharmacol. 135 (2002) 1144-1151
7. Briejer M.R., Akkermans L.M., and Schuurkes J.A. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol. Rev. 47 (1995) 631-651
8. 3 antagonist treatment?. Neurogastroenterol. Motil. 19 (2007) 77-84
9. Camilleri M., Kerstens R., Rykx A., and Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N. Engl. J. Med. 358 (2008) 2344-2354
10. Chang L., Chey W.D., Harris L., Olden K., Surawicz C., and Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am. J. Gastroenterol. 101 (2006) 1069-1079
11. Coulie B., Tack J., Maes B., Geypens B., De Roo M., and Janssens J. Sumatriptan, a selective 5-HT1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am. J. Physiol. 272 (1997) G902-G908
12. Craig D.A., and Clarke D.E. Pharmacological characterization of a neuronal receptor for 5-hydroxytryptamine in guinea pig ileum with properties similar to the 5-hydroxytryptamine receptor. J. Pharmacol. Exp. Ther. 252 (1990) 1378-1386
13. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., and Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80 (1995) 795-803
14. De Maeyer J.H., Lefebvre R.A., and Schuurkes J.A.J. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol. Motil. 20 (2008) 99-112
15. Dumuis A., Bouhelal R., Sebben M., Cory R., and Bockaert J. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol. Pharmacol. 34 (1988) 880-887
16. Evans B.W., Clark W.K., Moore D.J., and Whorwell P.J. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. 1 (2004) CD003960
17. Gallo-Torres H., Brinker A., and Avigan M. Alosetron: ischemic colitis and serious complications of constipation. Am. J. Gastroenterol. 101 (2006) 1080-1083
18. Gershon M.D., and Tack J. Thee selotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132 (2007) 397-414
19. Holtmann G., and Talley N.J. Functional dyspepsia. Current treatment recommendations. Drugs 45 (1993) 918-930
20. Itoh Z., Honda R., Takeuchi S., Aizawa I., and Takayanagi R. An extraluminal force transducer for recording contractile activity of the gastrointestinal smooth muscle in the conscious dogs: its construction and implantation. Gastroenterol. Jpn. 12 (1977) 275-283
21. Itoh Z., and Sekiguchi T. Interdigestive motor activity in health and disease. Scand. J. Gastroenterol., Suppl. 82 (1983) 121-134
22. Kahrilas P.J., Quigley E.M., Castell D.O., and Spechler S.J. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oseophageal reflux disease. Aliment. Pharmacol. Ther. 14 (2000) 1503-1509
23. Karasawa T., Yoshida N., Furusawa K., Omoya H., and Ito T. Comparison of gastrokinetic effects of AS-4370, cisapride and BRL24924. Eur. J. Pharmacol. 183 (1990) 2181
24. Kojima T., Sugano K., Onoue S., Murase N., Sato M., Kawabata Y., and Mano T. Solid form selection of zwitterionic 5-HT4 receptor agonist. Int. J. Pharm. 350 (2008) 35-42
25. Komada T., and Yano S. Pharmacological characterization of 5-Hydroxytryptamine-receptor subtypes in circular muscle from the rat stomach. Biol. Pharm. Bull. 30 (2007) 508-513
26. 4 receptor ligands: applications and new prospects. J. Med. Chem. 46 (2003) 319-344
27. Lesbros-Pantoflickova D., Michetti M., Fried C., Beglinger A., and Blum L. Meta-analysis: the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 20 (2004) 1253-1269
28. Maddern G.J., Jamieson G.G., Myers J.C., and Collins P.J. Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease. Gut 32 (1991) 470-474
29. Mayer E.A., and Bradesi S. Alosetron and irritable bowel syndrome. Expert Opin. Pharmacother. 4 (2003) 2089-2098
30. 4 agonist activities of tegaserod in the anaesthetized rat. Pharmacol. Res. 53 (2006) 353-358
31. Mikami T., Ochi Y., Suzuki K., Saito T., Sugie Y., and Sakakibara M. 5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-α]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscious dogs. J. Pharmacol. Exp. Ther. 325 (2008) 190-199
32. 4-receptor agonists. J. Pharmacol. Sci. 107 (2008) 251-259
33. + channel by the gastrointestinal prokinetics agent cisapride. Am. J. Physiol. 273 (1997) H2534-H2538
34. 4 partial agonist. J. Pharm. Sci. 97 (2008) 4307-4318
35. Onoue S., Kawamura K., Igarashi N., Zhou Y., Fujikawa M., Yamada H., Tsuda Y., Seto Y., and Yamada S. Reactive oxygen species assay-based risk assessment of drug-induced phototoxicity: classification criteria and application to drug candidates. J. Pharm. Biomed. Anal. 47 (2008) 967-972
36. Pehlivanov N., Sarosiek I., Whitman R., Olyaee M., and McCallum R. Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 16 (2002) 743-747
37. 7 receptors mediating relaxation of human colonic circular smooth muscle. Br. J. Pharmacol. 128 (1999) 849-852
38. Prins N.H., Akkermans L.M., Lefebvre R.A., and Schuurkes J.A. Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle. Br. J. Pharmacol. 134 (2001) 1351-1359
39. Quigley E.M., Vandeplassche L., Kerstens R., and Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomised, double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 29 (2009) 315-328
40. Rampe D., Roy M.-L., Dennis A., and Brown A.M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 417 (1997) 28-32
41. Rodoriguez-Stanley S., Zubaidi S., Proskin H.M., Kralstein J.R., Shetzline M.A., and Miner P.B. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin. Gastroenterol. Hepatol. 4 (2006) 442-450
42. Ruth M., Hamelin B., Röhss K., and Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 12 (1998) 35-40
43. Ruth M., Finizia C., Cange L., and Lundell L. The effect of mosapride on motor function and acid reflux in patients with gastro-oseophageal reflux. Eur. J. Gastroenterol. Hepatol. 15 (2003) 1115-1121
44. 4 receptor in the human stomach. Jpn. J. Pharmacol. 79 (1999) 493-496
45. Kr potassium channel. Cell 81 (1995) 299-307
46. Sato F., Marui S., Inatomi N., Itoh Z., and omura S. EM574, an erythromycin derivative, improves delayed gastric emptying of semi-solid meals in conscious dogs. Eur. J. Pharmacol. 395 (2000) 165-172
47. Spiller R.C. Effects of serotonin on intestinal secretion and motility. Curr. Opin. Gastroenterol. 17 (2001) 99-103
48. Tack J., Van Outryve M., Beyens G., Kerstens R., and Vandeplassche G. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients with dissatisfied with laxatives. Gut. 58 (2009) 357-365
49. Talley N.J. New and emerging treatments for irritable bowel syndrome and functional dyspepsia. Expert Opin. Emerg. Drugs 7 (2002) 91-98
50. 4-like receptor in human colon circular smooth muscle. Br. J. Pharmacol. 115 (1995) 172-176
51. Thompson C.A. Novartis suspends tegaserod sales at FDA's request. 2007. Am. J. Health-Syst. Pharm. 65 (2008) 1667-1670
52. 4 agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J. Pharm. Sci. 105 (2007) 207-210
53. Tonini M., and Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig. Dis. 24 (2006) 59-69
54. 2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment. Pharmacol. Ther. 19 (2004) 379-390
55. Walker B.D., Singleton C.B., Bursill L.A., Wyse K.R., Valenzuela S.M., Qiu M.R., Breit S.N., and Campbell T.J. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br. J. Pharmacol. 128 (1999) 444-450
56. Wienbeck M., and Li Q. Cisapride in gastro-oesophageal reflux disease: effects on oesophageal motility and intra-oesophageal pH. Scand. J. Gastroenterol., Suppl. 165 (1989) 13-18 (discussion 27-28)
57. Willems J.L., Buylaert W.T., Lefebvre R.A., and Bogaert M.G. Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol. Rev. 37 (1985) 165-216
58. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J.C., Robertson G.A., and January C.T. Properties of HERG channels stably expressed in HEK 293 cells studies at physiological temperature. Biophys. J. 74 (1998) 230-241